Fischer, Laura E. http://orcid.org/0000-0001-8752-5827
Stintzing, Sebastian
von Weikersthal, Ludwig Fischer
Modest, Dominik P.
Decker, Thomas
Kiani, Alexander http://orcid.org/0000-0002-2494-4087
Kaiser, Florian
Al-Batran, Salah-Eddin
Heintges, Tobias
Lerchenmüller, Christian
Kahl, Christoph
Seipelt, Gernot
Kullmann, Frank
Stauch, Martina
Scheithauer, Werner
Giessen-Jung, Clemens
Uhlig, Jens
Peuser, Bettina
Denzlinger, Claudio
Stahler, Arndt
Weiss, Lena
Heinrich, Kathrin
Held, Swantje
Jung, Andreas
Kirchner, Thomas
Heinemann, Volker
Funding for this research was provided by:
Pfizer
Merck KGaA
Article History
Received: 26 April 2021
Revised: 14 April 2022
Accepted: 9 May 2022
First Online: 30 May 2022
Competing interests
: LEF<b>:</b> No conflicts of interests. SS: Honoraria: AMGEN, Bayer, BMS, ESAI, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, Takeda, Financial relationships: Merck KGaA, Pierre-Fabre, Servier, Roche. Advisory role: AMGEN, Bayer, BMS, ESAI, Lilly, Merck KGaA, MSD, Pierre-Fabre, Roche, Sanofi, Servier, Taiho, Takeda. LFvW: Honoraria: Novartis, Lilly, Piere-Fabre and Roche Pharma AG. DPM: Honoraria: Merck Serono, Amgen, Roche, Servier, BMS, MSD, Pierre Fabre, Onkowissen.de, Taiho, Sanofi, Eli Lilly. Consulting or Advisory Role: Merck Serono, Amgen, Bayer, Incyte, Servier, BMS, Onkowissen.de. Research Funding: Amgen (Inst), Servier (Inst). Travel, Accommodations, Expenses: Amgen, Merck Serono, Servier, Bristol-Myers Squibb. TD: Advisory Role: Roche and Novartis. AK: Honoraria: Merck and Roche. FK: Advisory Role: Elsevier, Astellas, MSD, Novartis, Servier, GSK. S-EA-B: No conflicts of interests. TH; No conflicts of interests. CL: No conflicts of interests. CK: No conflicts of interests. GS: No conflicts of interests. FK: No conflicts of interests. MS: No conflicts of interests. WS: No conflicts of interests. CG-J: Honoraria/Travel: Roche. JU: Adboards/Workshops: Roche, Amgen, Servier, MSD, Bristol-Myers Squibb, Sanofi, Merck, Celgene, Novartis, Janssen-Cilag, Boehringer-Ingelheim und Bayer, Biogene. BP: No conflicts of interests. CD: Financial relationships: Janssen, Novartis, Celgene, Incyte, Abbvie, Bayer, Merck. AS: Honoraria: Roche and Servier. Travel: Roche, Merck KGaA, MSD Sharp & Dohme, Pfizer and Amgen. LW: Honoraria: Roche and Servier. KH: No conflicts of interests. SH; No conflicts of interests. AJ: No conflicts of interests. TK: Consulting/Advisory: Amgen, AstraZeneca, BMS, Merck KGaA, MSD, Novartis, Pfizer, Roche. Research Funding: Merck and Roche. Advisory Role: Merck KGaA, Astra Zeneca. VH: Honoraria: Merck, Amgen, Roche, Sanofi, SIRTEX, Servier, Pfizer, Pierre-Fabre, Astra-Zeneca. Consulting: Merck, Amgen, Roche, Sanofi, SIRTEX, BMS; MSD, Novartis, Boehringer Ingelheim, Servier, Pierre-Fabre, Celgene, Terumo. Research funding (for the institution): Merck, Amgen, Roche, Sanofi, Pfizer, Boehringer-Ingelheim, Sirtex, Bayer, Servier. Travel accommodation expenses: Merck, Roche, Amgen, SIRTEX, Bayer, Servier.
: The protocol and informed consent forms were approved by the ethic committee of the Medical Faculty of the Ludwig-Maximilians-University (reference number: 370-06). Informed consent was obtained from all subjects prior to participating in the study. The study was conducted in accordance with the Declaration of Helsinki.